Xoma Royalty Corporation is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments for various diseases
The company focuses on acquiring and managing a portfolio of royalty interests in therapeutic assets, partnering with biotechnology and pharmaceutical firms to maximize the potential of its investment in cutting-edge therapies. Xoma's strategy often includes collaborating on late-stage clinical developments, allowing it to benefit from future sales and royalties generated by successful product launches, thus driving its mission to enhance patient outcomes while pursuing financial growth through its diverse royalty-based business model.
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.
Earlier today, XOMA Corporation (NASDAQXOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin
XOMA (NASDAQXOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%, reporting an EPS of $-0.98 versus an estimate of $-0.5.
XOMA (NASDAQXOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%, reporting an EPS of $-0.98 versus an estimate of $-0.5.
XOMA (NASDAQXOMA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:45 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 108.7%, reporting an EPS of $-0.48 versus an estimate of $-0.23.
